Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03823144CT.gov Intravital Microscopy in Human Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Soluble Fluorescein (this asset) | Mayo Clinic | N/A | D · 30 |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | A |
| Camizestrant | AstraZeneca | P3 | BBB |
| Trastuzumab Emtansine | SWOG Cancer Research Network | P3 | BBB |
| Etoposide | Fudan University | P3 | BBB |
| Toripalimab | Zhejiang Cancer Hospital | P4 | BBB |
| Indocyanine Green | Isabelle Henskens | P3 | BBB |
| Everolimus | UNC Lineberger Comprehensive Cancer Center | P4 | BBB |
| Adriamycin | George Washington University | P4 | BBB |
+42 more in the Breast Cancer cohort
Other indications for Soluble Fluorescein
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | Early P1 | CC · 43 |
| Ovarian Cancer | — | Early P1 | CC · 43 |
| Ovarian Carcinoma | — | Early P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
98Moderate confidence
Detailed axis rationale is planned and will be published soon.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Soluble Fluorescein in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 15, 2026. Accessed July 16, 2026. https://terminal.floatz.ai/assets/soluble-fluorescein-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →